CN101044117A - 用于治疗缺血性损伤的4－[(2,4－二氯－5－甲氧基苯基)氨基]－6－烷氧基－7－乙炔基－3－氰喹啉 - Google Patents

用于治疗缺血性损伤的4－[(2,4－二氯－5－甲氧基苯基)氨基]－6－烷氧基－7－乙炔基－3－氰喹啉 Download PDF

Info

Publication number
CN101044117A
CN101044117A CNA2005800360383A CN200580036038A CN101044117A CN 101044117 A CN101044117 A CN 101044117A CN A2005800360383 A CNA2005800360383 A CN A2005800360383A CN 200580036038 A CN200580036038 A CN 200580036038A CN 101044117 A CN101044117 A CN 101044117A
Authority
CN
China
Prior art keywords
arbitrary
compound
amino
patient
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800360383A
Other languages
English (en)
Chinese (zh)
Inventor
黛安娜·哈里斯·博斯谢利
玛格丽特·扎列斯卡
安娜·卡罗莱娜·巴里奥斯－索莎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101044117A publication Critical patent/CN101044117A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
CNA2005800360383A 2004-10-22 2005-10-21 用于治疗缺血性损伤的4－[(2,4－二氯－5－甲氧基苯基)氨基]－6－烷氧基－7－乙炔基－3－氰喹啉 Pending CN101044117A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22
US60/621,280 2004-10-22

Publications (1)

Publication Number Publication Date
CN101044117A true CN101044117A (zh) 2007-09-26

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800360383A Pending CN101044117A (zh) 2004-10-22 2005-10-21 用于治疗缺血性损伤的4－[(2,4－二氯－5－甲氧基苯基)氨基]－6－烷氧基－7－乙炔基－3－氰喹啉

Country Status (23)

Country Link
US (1) US20060116375A1 (enExample)
EP (1) EP1802581B1 (enExample)
JP (1) JP2008517924A (enExample)
KR (1) KR20070085413A (enExample)
CN (1) CN101044117A (enExample)
AT (1) ATE391122T1 (enExample)
AU (1) AU2005299822A1 (enExample)
BR (1) BRPI0516995A (enExample)
CA (1) CA2581807A1 (enExample)
CR (1) CR9072A (enExample)
DE (1) DE602005005843T2 (enExample)
DK (1) DK1802581T3 (enExample)
EC (1) ECSP077385A (enExample)
ES (1) ES2303287T3 (enExample)
IL (1) IL182547A0 (enExample)
MX (1) MX2007004833A (enExample)
NO (1) NO20071708L (enExample)
PL (1) PL1802581T3 (enExample)
PT (1) PT1802581E (enExample)
RU (1) RU2007111704A (enExample)
SI (1) SI1802581T1 (enExample)
WO (1) WO2006047262A1 (enExample)
ZA (1) ZA200703275B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
CN103848785A (zh) * 2012-12-04 2014-06-11 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851A (zh) * 2022-01-17 2022-05-06 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
CN103848785A (zh) * 2012-12-04 2014-06-11 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851A (zh) * 2022-01-17 2022-05-06 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Also Published As

Publication number Publication date
NO20071708L (no) 2007-07-13
MX2007004833A (es) 2007-05-16
CR9072A (es) 2007-09-07
JP2008517924A (ja) 2008-05-29
US20060116375A1 (en) 2006-06-01
WO2006047262A1 (en) 2006-05-04
ATE391122T1 (de) 2008-04-15
KR20070085413A (ko) 2007-08-27
DK1802581T3 (da) 2008-06-30
DE602005005843T2 (de) 2009-05-14
EP1802581A1 (en) 2007-07-04
AU2005299822A1 (en) 2006-05-04
CA2581807A1 (en) 2006-05-04
DE602005005843D1 (de) 2008-05-15
ES2303287T3 (es) 2008-08-01
HK1104555A1 (en) 2008-01-18
SI1802581T1 (sl) 2008-08-31
RU2007111704A (ru) 2008-11-27
IL182547A0 (en) 2007-09-20
EP1802581B1 (en) 2008-04-02
PT1802581E (pt) 2008-06-03
PL1802581T3 (pl) 2008-09-30
ZA200703275B (en) 2008-08-27
BRPI0516995A (pt) 2008-09-30
ECSP077385A (es) 2007-05-30

Similar Documents

Publication Publication Date Title
EP1363900B1 (en) Isoindole-imide compounds, compositions and uses thereof
JP6141568B1 (ja) 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩
RU2339636C2 (ru) Гексагидропиридоизохинолины в качестве ингибиторов дипептидилпептидазы iv (dpp-iv)
CN1639164A (zh) 含氮杂环化合物
MX2012009541A (es) Derivados de ciclobutano y metilciclobutano como inhibidores de janus cinasa.
CA2849751A1 (en) Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof
TW202028180A (zh) 作為神經元組織胺受體－３拮抗劑之化合物及其用途
WO2016192132A1 (zh) 作为alk抑制剂的嘧啶衍生物
CN1795194A (zh) 新的吡啶并吡嗪类化合物及其用作激酶抑制剂的用途
CN1069643C (zh) 抑制巨细胞病毒的二氮杂萘及其类似物
CN1449398A (zh) 2－吡啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮和7－吡啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1H)酮衍生物
US20040229880A1 (en) 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
CN101874022A (zh) 吲唑丙烯酸酰胺化合物
CN1167698C (zh) 用作神经激肽受体拮抗剂的n-三唑基甲基哌嗪衍生物
KR101132378B1 (ko) 신경발생을 자극 및 신경 퇴화를 억제하는 방법 및 조성물
CN101044117A (zh) 用于治疗缺血性损伤的4－[(2,4－二氯－5－甲氧基苯基)氨基]－6－烷氧基－7－乙炔基－3－氰喹啉
CN114790207A (zh) 作为pi3k/mtor抑制剂的被取代的吡啶基取代的稠合喹啉化合物
CN1330654A (zh) 4,5－吡咯并羟吲哚
CN110753691A (zh) 化合物
CN111410667A (zh) 新型(1,2,4)三唑并(1,5-a)吡啶基磷氧化物及其用途
KR101657616B1 (ko) 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
CN1671708A (zh) 新的环烷二酮衍生物、它们的制备方法和它们的药物应用
HK1104555B (en) 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury
CN101087610A (zh) 芳基哌嗪衍生物及其作为5－ht1a受体配体的用途
AU2013245563A1 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20070926

C20 Patent right or utility model deemed to be abandoned or is abandoned